Literature DB >> 19396855

Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.

Ayalew Tefferi1, Ruben A Mesa, Animesh Pardanani, Kebede Hussein, Susan Schwager, Curtis A Hanson, David P Steensma.   

Abstract

Serum ferritin level at diagnosis was available in 185 patients with primary myelofibrosis (PMF); twenty-two (12%) patients had serum ferritin >1,000 ng/mL and 32 (17%) were red blood cell (RBC) transfusion-dependent. As expected, RBC transfusion need and increased serum ferritin displayed strong correlation (P < 0.0001); in addition, the latter but not the former correlated with advanced age (P < 0.0001). During median follow-up of 28 months (range 0.5-231), peak serum ferritin levels exceeded 1,000 ng/mL in 41 (22%) patients. On multivariable analysis that included age as a covariate, RBC transfusion need at diagnosis (P < 0.0001), but not increased serum ferritin or transfusion load, predicted shortened survival. The prognostic relevance of RBC transfusion need was independent of the International Prognostic Scoring System and was also illustrated for leukemia-free survival (P = 0.003). In PMF, the presence of a more severe erythropoietic defect, and not iron overload, has additional adverse prognostic value.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19396855     DOI: 10.1002/ajh.21391

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

1.  Prognostication in primary myelofibrosis.

Authors:  Francisco Cervantes; Arturo Pereira
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis.

Authors:  Animesh Pardanani; Ayalew Tefferi
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

3.  Myelodysplastic syndromes--many new drugs, little therapeutic progress.

Authors:  Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2010-09-22       Impact factor: 7.616

4.  One thousand patients with primary myelofibrosis: the mayo clinic experience.

Authors:  Ayalew Tefferi; Terra L Lasho; Thitina Jimma; Christy M Finke; Naseema Gangat; Rakhee Vaidya; Kebede H Begna; Aref Al-Kali; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

Review 5.  The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

Review 6.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2019-01-24       Impact factor: 10.047

Review 7.  Leukemia secondary to myeloproliferative neoplasms.

Authors:  Andrew J Dunbar; Raajit K Rampal; Ross Levine
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

8.  Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.

Authors:  Chiara Elena; Francesco Passamonti; Elisa Rumi; Luca Malcovati; Luca Arcaini; Emanuela Boveri; Michele Merli; Daniela Pietra; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

Review 9.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

Review 10.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-03       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.